(23 Mar 2021) Mavrilimumab- 57% patients alive compared to 47% in the placebo group
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial https://doi.org/10.1016/S2665-9913(21)00070-9 NCT04399980, NCT04463004, and NCT04492514-Between May 28 and Sept 15, 2020, 40 patients were enrolled and randomly assigned to mavrilimumab (n=21)… Continue reading "(23 Mar 2021) Mavrilimumab- 57% patients alive compared to 47% in the placebo group"